Zobair Younossi
0000-0001-9313-577X
35 papers found
Refreshing results…
Response to the letter: Hepatitis C screening in opioid epidemics in the United States and societal perspectives
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO
Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network
The epidemiology of nonalcoholic steatohepatitis: Epidemiology of NASH
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation: Younossi
The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review: Hepatology Elsewhere
The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C
Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3
Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France
In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease: Hepatology Communications, Vol. XX, No. X, 2017
Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States
A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD
Missing publications? Search for publications with a matching author name.